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Abstract
Whether it is the primary reason for admission or a complication of
critical illness, upper gastrointestinal bleeding is commonly
encountered in the intensive care unit. In this setting, in the absence
of endoscopy, intensivists generally provide supportive care
(transfusion of blood products) and acid suppression (such as
proton pump inhibitors). More recently, octreotide (a somatostatin
analogue) has been used in such patients. However, its precise role
in patients with upper gastrointestinal bleeding is not necessarily
clear and the drug is associated with significant costs. In this issue
of  Critical Care, two expert teams debate the merits of using
octreotide in non-variceal upper gastrointestinal bleeding.
Clinical scenario
A 59 year old male has been admitted to the intensive care unit
with febrile neutropenia and septic shock. The patient has been
diagnosed with acute myelogenous leukemia and following
induction is pancytopenic. He is mechanically ventilated and
receiving H2 antagonists. You are called because the patient is
having large amounts of melena and a modest amount of blood
returning from his nasogastric tube. He is hemodynamically
unstable. You transfuse blood, platelets and plasma as
appropriate, and start an intravenous proton pump inhibitor.
Endoscopy cannot be performed until the following day. You
have to decide whether to treat the patient empirically with
intravenous octreotide. You know it has a role in certain types
of gastrointestinal (GI) bleeding but you are uncertain if you
should be using it when the cause of bleeding is unclear. Your
administrator tells you the drug is relatively expensive.
Review
Pro/con debate: Octreotide has an important role in the
treatment of gastrointestinal bleeding of unknown origin?
Yaseen Arabi1, Bandar Al Knawy2, Alan N Barkun3 and Marc Bardou4
1Intensive Care Unit, King Abdulaziz Medical City, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11426,
Saudi Arabia
2Division of Gastroenterology/Hepatology, Department of Medicine, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia
3Divisions of Gastroenterology and Clinical Epidemiology, McGill University, and the McGill University Health Centre, Montréal, Québec, Canada
4Division of Clinical Pharmacology, LPPCE, Faculty of Medicine, Dijon Cedex, France
Corresponding author: Alan Barkun, alan.barkun@muhc.mcgill.ca
Published: 3 July 2006 Critical Care 2006, 10:218 (doi:10.1186/cc4958)
This article is online at http://ccforum.com/content/10/4/218
© 2006 BioMed Central Ltd
GI = gastrointestinal; NVUGB = non-variceal upper gastrointestinal bleeding; PPI = proton pump inhibitor; RCT = randomized controlled trial; UGB =
upper gastrointestinal bleeding.
Pro: Yes, octreotide does have an important role in the treatment of gastrointestinal bleeding
of unknown origin
Yaseen Arabi and Bandar Al Knawy
There is evidence to support the use of octreotide in variceal
and non-variceal upper GI bleeding (UGB). As a somatostatin
analogue, octreotide binds with endothelial cell somatostatin
receptors, inducing strong, rapid and prolonged vaso-
constriction [1]. Octreotide reduces portal and variceal
pressures as well as splanchnic and portal-systemic collateral
blood flows [2]. It also prevents postprandial splanchnic
hyperemia in patients with portal hypertension [3] and lowers
gastric mucosal blood flow in normal and portal hypertensive
stomachs [4]. Octreotide inhibits both acid and pepsin
secretion. As a result, it prevents the dissolution of freshly
formed clots at the site of bleeding [5].
The use of octreotide as a first, single therapy versus
emergency sclerotherapy in bleeding esophageal varices was
examined in a Cochrane systematic review of 12 randomized
controlled trials (RCTs), including 6 trials of octreotide [6].
Emergency sclerotherapy was not significantly superior to
any of the pharmacological treatments with regard to the
assessed efficacy outcomes. In fact, adverse events werePage 2 of 4
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significantly more frequent with sclerotherapy [6]. Octreotide
is also effective as an adjunct to endoscopic therapy of
variceal bleeding [7]. In patients with bleeding from portal
hypertensive gastropathy, octreotide was found to be more
effective than vasopressin and omeprazole in achieving
complete bleeding control with less time and fewer blood
transfusions required to control bleeding [8].
Octreotide may also be effective in non-variceal UGB
(NVUGB). In a meta-analysis, somatostatin or octreotide were
compared to H2 antagonists and placebo and found to
reduce the risk for continued bleeding or rebleeding. The
drugs were efficacious for peptic ulcer bleeding and showed
a trend toward efficacy for non-peptic ulcer bleeding (mostly
caused by gastritis). However, the quality of some of the
included studies has been questioned [9]. In addition, the
comparison with H2 blockers or placebo is less relevant to
current practice considering the proven superiority of proton-
pump inhibitors [10]. The panel of the Nonvariceal Upper GI
Bleeding Consensus did not support the routine use of
somatostatin or octreotide in non-variceal UGB. However,
because of the favorable safety profile, the panel suggested
that somatostatin or octreotide might be useful for patients
with uncontrollable bleeding awaiting endoscopy or awaiting
surgery or for whom surgeryis contraindicated [11].
UGB in critically ill patients has major consequences. Studies
have demonstrated that UGB is associated with a significant
attributable mortality (relative risk 4.1, 95% confidence
interval 2.6 to 6.5) and length of intensive care unit stay
(7.9 days, 95% confidence interval 1.4 to 14.4 days). Each
episode resulted in a mean of 11 blood product transfusions,
and 24 days of treatment, leading to an attributable cost of
$12,000 [12]. Unfortunately, data about the efficacy and cost
effectiveness of octreotide in critically ill patients are lacking.
However, octreotide has several features that make its use
favorable in this population; it can be started quickly without
the need for someone with endoscopy training to initiate, it
has a relatively rapid onset of action and is relatively free of
significant adverse effects [13].
In summary, in the absence of RCTs, the existing evidence of
efficacy along with the favorable benefit-risk profile support
the decision to use octreotide as an initial empirical therapy in
critically ill patients with active UGB awaiting more definitive
endoscopic diagnostic and therapeutic interventions.
Con: Octreotide prior to upper endoscopy for bleeding
Alan N Barkunand Marc Bardou
The following discussion focuses on NVUGB as the current
patient is much less likely to have portal hypertension.
Current guidelines do not recommend routine octreotide in
NVUGB [11]. In contrast, high dose proton pump inhibitors
(PPIs) improve outcomes of patients at high risk of peptic
ulcer rebleeding, including mortality [10,11,14,15]. The
resultant profound acid suppression probably stabilizes clot
[11] and, possibly, accelerates healing of bleeding lesions
over the 72 hours following endoscopic hemostasis [16,17].
Somatostatin and octreotide inhibit acid, and decrease both
pepsin secretion and gastroduodenal mucosal blood flow
[5,18]; but the impact on patient outcomes may differ
between both agents [5,18]. A meta-analysis has suggested
that somatostatin (12 studies) and octreotide (2 studies)
improved outcomes versus placebo or H2-receptor antago-
nists (thought to be equivalent to placebo [19,20]) in patients
with NVUGB [21]. Yet 13 of the 14 included RCTs were
carried out before 1989. Standards of care have significantly
evolved since then. More contemporary RCTs, totaling 242
patients, have shown no benefits attributable to somatostatin
or octreotide, either alone or with ranitidine, compared to the
control group administration (placebo or ranitidine) [22-24],
except for a subgroup of 15 patients with oozing ulcers [24].
In one of few head-to-head comparisons with PPIs, human
gastric pH data showed enhanced acid suppression for
octreotide compared to pantoprazole. However, the acid
suppressing effect of pantoprazole was less than previously
reported [25], and differences disappeared after the initial 6
to 12 hours of the 24 hour intravenous infusions [26]. An
older, underpowered RCT showed no difference in outcomes
between omeprazole and a combination of somatostatin and
ranitidine in severe GI bleeding [27].
It is thus unlikely that somatostatin or octreotide can improve
on results of high dose PPIs in patients with NVUGB,
particularly bleeding ulcers, following endoscopic hemo-
stasis. But what about administration to patients while
awaiting endoscopy?
PPI infusion prior to endoscopy decreases the proportion of
patients subsequently found to have high risk ulcer stigmata
[16,17], but does not improve outcomes. It is unlikely,
therefore, that somatostatin or octreotide would help in a
patient population bleeding principally from NVUGB - the
usual setting as this group comprises 80% to 90% of all
bleeders seen [28]. Because of their effect on decreasing
portal pressure, somatostatin and analogues have been used
in acute variceal bleeding. In this patient population, meta-
analyses [29] have shown no benefit of somatostatin over
placebo in improving outcomes, while octreotide was no
better than immediate sclerotherapy [30]; none, including
vapreotide [31], decreased mortality at follow-up, although
the latter two agents improved control of bleeding.Page 3 of 4
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In conclusion, there exists no reason to initiate intravenous
octreotide in the current setting, based on published efficacy
data, let alone cost considerations. Somatostatin or
octreotide can be considered in patients with NVUGB on a
case-by-case basis, as additional pharmacotherapy, while
awaiting endoscopy in very actively bleeding patients [11].
However, the definitive treatment of all patients with NVUGB
remains early endoscopy as it has been shown to yield
accurate diagnosis and prognostication, while improving
outcomes and the cost-effective management of patients at
high and low risk of rebleeding [11].
Available online http://ccforum.com/content/10/4/218
Pro’s response: Defining the indication
Yaseen Arabi and Bandar Al Knawy
Octreotide use as an adjunct to endoscopic therapy
[21,24,32] should be distinguished from its use as an initial
therapy awaiting endoscopy [6]. The latter application in
NVUGB is not well studied. However, octreotide as a first
therapy for variceal bleeding was found to be as effective as
emergency sclerotherapy with less adverse events [6].
Octreotide is not a substitute for PPIs or endoscopy. How-
ever, the latter is not always available or medically possible;
only 19% of endoscopies were performed after working
hours in one study [33]. Therefore, in our patient with active
bleeding awaiting endoscopy, we will follow the consensus
statement and initiate octreotide infusion[11].
Con’s response: Octreotide prior to upper endoscopy for bleeding
Alan N Barkunand Marc Bardou
Octreotide is useful in patients with UGB, but its routine
administration prior to endoscopy is supported neither by
existing efficacy data nor cost benefit studies. Published
evidence has guided a Consensus panel to recommend its
use, on a case-by-case basis, in patients with very active
bleeding while waiting for endoscopy hemostasis or surgery
[11]. It is probably also reasonable to consider administration
in patients with a high probability of an esophageal variceal
bleeding prior to endoscopy with possible banding. The
mainstay of diagnosis and mortality-improving treatment for
patients with peptic ulcers at high risk of rebleeding remains
early endoscopy.
Competing interests
AB is a consultant for AstraZeneca and Atlana Pharma.
References
1. Reubi JC, Schaer JC, Laissue JA, Waser B: Somatostatin recep-
tors and their subtypes in human tumors and in peritumoral
vessels. Metabolism 1996, 45(Suppl 1):39-41.
2. Nevens F: Review article: a critical comparison of drug thera-
pies in currently used therapeutic strategies for variceal
haemorrhage. Aliment Pharmacol Ther 2004, 20(Suppl 3):18-
22; discussion 23.
3. Ludwig D, Schadel S, Bruning A, Schiefer B, Stange EF: 48-hour
hemodynamic effects of octreotide on postprandial splanch-
nic hyperemia in patients with liver cirrhosis and portal hyper-
tension: double-blind, placebo-controlled study. Dig Dis Sci
2000, 45:1019-1027.
4. Clarke DL, McKune A, Thomson SR: Octreotide lowers gastric
mucosal blood flow in normal and portal hypertensive stom-
achs. Surg Endosc 2003, 17:1570-1572.
5. Sgouros SN, Bergele C, Viazis N, Avgerinos A: Somatostatin
and its analogues in peptic ulcer bleeding: facts and patho-
physiological aspects. Dig Liver Dis 2006, 38:143-148.
6. D’Amico G, Pietrosi G, Tarantino I, Pagliaro L: Emergency scle-
rotherapy versus medical interventions for bleeding
oesophageal varices in cirrhotic patients. Cochrane Database
Syst Rev 2002;(1):CD002233.
7. Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-
Arbol L, Salcedo M, Molinero LM: Endoscopic treatment versus
endoscopic plus pharmacologic treatment for acute variceal
bleeding: a meta-analysis. Hepatology 2002, 35:609-615.
8. Zhou Y, Qiao L, Wu J, Hu H, Xu C: Comparison of the efficacy
of octreotide, vasopressin, and omeprazole in the control of
acute bleeding in patients with portal hypertensive gastropa-
thy: a controlled study. J Gastroenterol Hepatol 2002, 17:973-
979.
9. Palmer KR: Non-variceal upper gastrointestinal haemorrhage:
guidelines. Gut 2002, 51:1iv-6.
10. Leontiadis GI, Sharma VK, Howden CW: Systematic review and
meta-analysis of proton pump inhibitor therapy in peptic ulcer
bleeding. BMJ 2005, 330:568-575.
11. Barkun A, Bardou M, Marshall JK, for the Nonvariceal Upper
GIBCCG:  Consensus Recommendations for Managing
Patients with Nonvariceal Upper Gastrointestinal Bleeding.
Ann Intern Med 2003, 139:843-857.
12. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland
DK, Kirby A, Tryba M: The attributable mortality and length of
intensive care unit stay of clinically important gastrointestinal
bleeding in critically ill patients. Crit Care 2001, 5:368-375.
13. Erstad BL: Octreotide for acute variceal bleeding. Ann Pharma-
cother 2001, 35:618-626.
14. Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG,
Quitadamo M, Merla A, Fiorella S, Leandro G: Proton-pump
inhibitors and outcome of endoscopic hemostasis in bleeding
peptic ulcers: a series of meta-analyses. Am J Gastroenterol
2005, 100:207-219.
15. Khuroo MS, Farahat KL, Kagevi IE: Treatment with proton pump
inhibitors in acute non-variceal upper gastrointestinal bleed-
ing: a meta-analysis. J Gastroenterol Hepatol 2005, 20:11-25.
16. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG,
Walt RP: Omeprazole versus placebo for acute upper gas-
trointestinal bleeding: randomised double blind controlled
trial. BMJ 1992, 304:143-147.17. Lau JY, Leung WK, Wu JC, Chan FK, Wong V, Hung LC, Cheung
K, Yung M, Lee VW, Chiu PW, et al.: Early administration of
high-dose intravenous omeprazole prior to endoscopy in
patients with upper gastrointestinal bleeding; a double blind
placebo controlled randomized trial. Gastroenterology  2005,
128:A-50.
18. Kubba AK, Dallal H, Haydon GH, Hayes PC, Palmer KR: The
effect of octreotide on gastroduodenal blood flow measured
by laser Doppler flowmetry in rabbits and man. Am J Gas-
troenterol 1999, 94:1077-1082.
19. Collins R, Langman M: Treatment with histamine H2 antago-
nists in acute upper gastrointestinal hemorrhage. Implica-
tions of randomized trials. N Engl J Med 1985, 313:660-666.
20. Levine JE, Leontiadis GI, Sharma VK, Howden CW: Meta-analy-
sis: the efficacy of intravenous H2-receptor antagonists in
bleeding peptic ulcer. Aliment Pharmacol Ther 2002, 16:1137-
1142.
21. Imperiale TF, Birgisson S: Somatostatin or octreotide com-
pared with H2 antagonists and placebo in the management of
acute nonvariceal upper gastrointestinal hemorrhage: a meta-
analysis. Ann Intern Med 1997, 127:1062-1071.
22. Archimandritis A, Tsirantonaki M, Tryphonos M, Kourtesas D, Sou-
gioultzis S, Papageorgiou A, Tzivras M: Ranitidine versus raniti-
dine plus octreotide in the treatment of acute non-variceal
upper gastrointestinal bleeding: a prospective randomised
study. Curr Med Res Opin 2000, 16:178-183.
23. Nikolopoulou VN, Thomopoulos KC, Katsakoulis EC, Vasilopoulos
AG, Margaritis VG, Vagianos CE: The effect of octreotide as an
adjunct treatment in active nonvariceal upper gastrointestinal
bleeding. J Clin Gastroenterol 2004, 38:243-247.
24. Okan A, Simsek I, Akpinar H, Ellidokuz E, Sanul AR, Aksoz K:
Somatostatin and ranitidine in the treatment of non-variceal
upper gastrointestinal bleeding: a prospective, randomized,
double-blind, controlled study. Hepatogastroenterology  2000,
47:1325-1327.
25. van Rensburg CJ, Hartmann M, Thorpe A, Venter L, Theron I,
Luhmann R, Wurst W: Intragastric pH during continuous infu-
sion with pantoprazole in patients with bleeding peptic ulcer.
Am J Gastroenterol 2003, 98:2635-26341.
26. Avgerinos A, Sgouros S, Viazis N, Vlachogiannakos J, Papaxoinis
K, Bergele C, Sklavos P, Raptis SA: Somatostatin inhibits
gastric acid secretion more effectively than pantoprazole in
patients with peptic ulcer bleeding: a prospective, random-
ized, placebo-controlled trial. Scand J Gastroenterol 2005, 40:
515-522.
27. Goletti O, Sidoti F, Lippolis PV, De Negri F, Cavina E: Omepra-
zole versus ranitidine plus somatostatin in the treatment of
severe gastroduodenal bleeding: a prospective, randomized,
controlled trial. Ital J Gastroenterol 1994, 26:72-74.
28. Boonpongmanee S, Fleischer DE, Pezzullo JC, Collier K, Mayoral
W, Al-Kawas F, Chutkan R, Lewis JH, Tio TL, Benjamin SB: The
frequency of peptic ulcer as a cause of upper-GI bleeding is
exaggerated. Gastrointest Endosc 2004, 59:788-794.
29. Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Bur-
charth F: Somatostatin v placebo in bleeding oesophageal
varices: randomised trial and meta-analysis. BMJ 1995, 310:
1495-1498.
30. Corley DA, Cello JP, Adkisson W, Ko WF, Kerlikowske K:
Octreotide for acute esophageal variceal bleeding: a meta-
analysis. Gastroenterology 2001, 120:946-954.
31. Cales P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-
Talbodec N, Bronowicki JP, Ribard D, Botta-Fridlund D, Hillon P,
et al.: Early administration of vapreotide for variceal bleeding
in patients with cirrhosis. N Engl J Med 2001, 344:23-28.
32. Gotzsche PC, Hrobjartsson A: Somatostatin analogues for
acute bleeding oesophageal varices. Cochrane Database Syst
Rev 2005;(1):CD000193.
33. Parente F, Anderloni A, Bargiggia S, Imbesi V, Trabucchi E, Baratti
C, Gallus S, Porro GB: Outcome of non-variceal acute upper
gastrointestinal bleeding in relation to the time of endoscopy
and the experience of the endoscopist: a two-year survey.
World J Gastroenterol 2005, 11:7122-7130.
Critical Care    Vol 10 No 4 Arabi et al.
Page 4 of 4
(page number not for citation purposes)